San Antonio, Texas, December 2, 2025
Plus Therapeutics, Inc. has announced that its innovative rhenium-based treatment for leptomeningeal metastases will be highlighted at the San Antonio Breast Cancer Symposium. The study shows promising results for advanced cancer patients, marking significant progress in oncology treatment. The FDA has already granted Fast Track and Orphan Drug designations, emphasizing the treatment’s potential to address unmet medical needs. Plus Therapeutics is committed to advancing its clinical trials, reflecting the vibrant biomedical landscape in San Antonio.
San Antonio, Texas – In an exciting development for the local biomedical landscape, Plus Therapeutics, Inc. (Nasdaq: PSTV) has confirmed that its research on the novel rhenium-based treatment for leptomeningeal metastases will be featured in a poster spotlight presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), set to take place from December 9-12, 2025. This presentation is an important step forward in addressing critical health challenges faced by cancer patients in the region.
Leptomeningeal metastases (LM) are a serious complication of advanced cancer, commonly seen in approximately 5% of metastatic cancer cases, primarily originating from breast cancer, lung cancer, and melanoma. In light of the limited treatment options currently available, Plus Therapeutics’ innovative approach offers a glimmer of hope, showcasing the spirit of entrepreneurial innovation that thrives in San Antonio.
Overview of Rhenium (186Re) Obisbemeda
The treatment, known as rhenium (186Re) obisbemeda or REYOBIQ, is a targeted radiotherapy aimed specifically at central nervous system tumors. Recent Phase 1 dose escalation study results revealed that 20 patients with LM showed promising outcomes. A critical aspect of this study demonstrated a linear increase in absorbed radiation dose in the cranial subarachnoid space, with a substantial average absorbed dose of 253 Gy in the final cohort.
The clinical benefit rate from this treatment was notable, exceeding 75%, with 31% of participants experiencing a partial response and several others maintaining stable disease. The median overall survival rate observed for these patients was reported at 12 months, indicating the treatment’s potential effectiveness.
Regulatory Progress and Designations
In recognition of its potential to address significant unmet medical needs, the FDA has awarded Fast Track and Orphan Drug designations to rhenium (186Re) obisbemeda for the treatment of LM in breast cancer patients. This regulatory support underscores the significance of the research and highlights the importance of fostering a supportive environment for innovators and small businesses, a crucial element for economic growth in sectors such as healthcare.
The Path Ahead for Plus Therapeutics
Plus Therapeutics is not resting on its laurels. The company is advancing its ReSPECT-LM clinical trial and plans to initiate a Phase 1b single-dose breast expansion cohort in the first quarter of 2025. This proactive approach reflects the resilience of local businesses and their commitment to delivering groundbreaking solutions in medical treatments.
Furthermore, the ongoing research into LM treatments has the potential to influence broader medical applications, contributing not just to patient care but also to the overall economy by attracting investments and fostering partnerships within the healthcare sector.
San Antonio’s Role in Biomedical Innovation
As Plus Therapeutics leads the charge in advancing cancer treatment options, it also emphasizes the vital role San Antonio plays in the biomedical innovation landscape. The city is becoming a hub for clinical research, supported by local entrepreneurs and institutions dedicated to improving health outcomes. Lower regulatory barriers could further enhance opportunities for growth and attract more clinical trials and startups to the area.
Encouraging stories such as this one demonstrate how local entrepreneurs, when given the right resources and environment, can spearhead critical advancements that benefit not only patients but the community as a whole.
Conclusion
The acceptance of Plus Therapeutics’ presentation at the SABCS reflects significant progress in the fight against leptomeningeal metastases and highlights San Antonio’s burgeoning biomedical sector. As the city continues to cultivate an atmosphere conducive to innovation and entrepreneurship, local residents are encouraged to support these efforts. Together, fostering small business success and contributing to the local economy can play a pivotal role in shaping a healthier future for all.
Frequently Asked Questions
What is rhenium (186Re) obisbemeda?
Rhenium (186Re) obisbemeda, also known as REYOBIQ, is a targeted radiotherapy designed for central nervous system tumors, including leptomeningeal metastases.
What are leptomeningeal metastases?
Leptomeningeal metastases are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. They occur in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources.
What were the results of the Phase 1 dose escalation study?
The study observed a linear increase in absorbed radiation dose to the cranial subarachnoid space, with an average absorbed dose of 253 Gy in Cohort 5. The clinical benefit rate was over 75%, with 31% of patients showing a partial response and an additional 7 patients exhibiting stable disease. The median overall survival for these patients was 12 months, with half of the participants still alive at the time of analysis.
What designations has the FDA granted to rhenium (186Re) obisbemeda?
The FDA has granted Fast Track and Orphan Drug designations to rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases in breast cancer patients.
What are the next steps for Plus Therapeutics?
Plus Therapeutics plans to initiate a Phase 1b single-dose breast expansion cohort in the first quarter of 2025 to further evaluate the safety and efficacy of rhenium (186Re) obisbemeda.
| Key Feature | Details |
|---|---|
| Event | Poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS) |
| Date | December 12, 2025 |
| Location | San Antonio, Texas |
| Presenter | Dr. Andrew Brenner, Professor at the University of Texas Health Science Center at San Antonio |
| Topic | Phase 1 dose escalation study results for rhenium (186Re) obisbemeda in leptomeningeal metastases |
| Clinical Benefit Rate | Over 75% |
| Median Overall Survival | 12 months |
| FDA Designations | Fast Track and Orphan Drug for treatment of leptomeningeal metastases in breast cancer patients |
| Next Steps | Initiate Phase 1b single-dose breast expansion cohort in Q1 2025 |
Deeper Dive: News & Info About This Topic
HERE Resources
Plus Therapeutics to Present Breakthrough Study on Cancer Treatment
Author: STAFF HERE SAN ANTONIO WRITER
The SAN ANTONIO STAFF WRITER represents the experienced team at HERESanAntonio.com, your go-to source for actionable local news and information in San Antonio, Bexar County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Fiesta San Antonio, San Antonio Stock Show & Rodeo, and Dia de los Muertos. Our coverage extends to key organizations like the Greater San Antonio Chamber of Commerce and United Way of San Antonio and Bexar County, plus leading businesses in retail, insurance, and energy that power the local economy such as H-E-B, USAA, and Valero Energy. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREDallas.com, and HEREHouston.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
